Semaglutide was not linked to eye disorders or retinopathy, but it was associated with a higher risk for NAION.

Saliva insulin levels were indicative of differences between normal and hyperinsulinemic responses in normoglycemic individuals.

The ketamine product KETARx produced by PharmaTher has been approved by the FDA for use in surgical pain management.